RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.

Autres langues Rapid Therapeutic Science Laboratories, Inc.

Actions

RTSL

US7534312043

Produits pharmaceutiques

Temps réel OTC Markets 21:44:20 22/01/2026			Varia. 5j.	Varia. 1 janv.
0,007000 ^USD	+366,67%		+6 900,00%	+366,67%

14/08/23	Rapid Therapeutic Science Laboratories, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2023	CI
12/05/23	Rapid Therapeutic Science Laboratories, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2023	CI

Autres langues

06/12/23	Rapid Therapeutic Science Laboratories : Change in Certifying Accountants - Form 8-K
14/08/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
12/05/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
30/03/23	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
30/03/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
30/03/23	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt
21/03/23	White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories’ Long-Term Strategy
13/12/22	Rapid Therapeutic Science Laboratories Updates Patents
10/11/22	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
10/11/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
12/08/22	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
12/08/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
26/07/22	Rapid Therapeutic Science Laboratories File S1 and completes Mid-Year Strategy Review
31/05/22	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K)
31/05/22	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding
11/05/22	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
11/05/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
28/04/22	Rapid Therapeutic Science Laboratories to Attend the Respiratory Drug Delivery (RDD) 2022 Conference
31/03/22	Rapid Therapeutic Science Laboratories Announces 1-for-25 Reverse Stock Split
16/03/22	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
16/03/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
16/03/22	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt
01/02/22	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K)
28/01/22	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.4 million in funding
21/01/22	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K)